Correlation between the rate of intravitreal injections, use of aflibercept as a second-line treatment and visual impairment for wet AMD in Finland.
aflibercept
anti-vascular endothelial growth factor
treat-and-extend regimen
visual impairment
wet age-related macular degeneration
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
02
09
2019
accepted:
25
01
2020
pubmed:
26
2
2020
medline:
26
2
2020
entrez:
26
2
2020
Statut:
ppublish
Résumé
To correlate the rate of intravitreal anti-VEGF injections and the use of aflibercept as a second-line treatment with visual impairment throughout Finland. Information related to anti-VEGF treatment, proportions of bevacizumab and aflibercept and new visual impairments due to wet age-related macular degeneration (AMD) was gathered from 5 university hospitals and 14 central hospital districts between 2015 and 2017 covering 232 568 injections and 1172 visual impairments. Between 2015 and 2017, the number of annual total anti-VEGF injections increased from 60 412 to 93 589 (+24.5% annual change) and of aflibercept injections from 8299 to 20 833 (+58.7% annual change). The 3-year average for total anti-VEGF injections ranged from 9.6 to 21.1 (median 13.3) per 1000 citizens between hospital districts and for aflibercept injections from 0.8 to 4.0 (median 1.9). According to the primary protocol for wet AMD, during 2015-2017, the number of total anti-VEGF injections increased from 10.9 to 15.2 per 1000 citizens with the pro re nata (PRN) protocol and from 11.3 to 18.9 with the treat-and-extend regimen (TER). The 3-year average of aflibercept injections as a second-line treatment, but not the total number of anti-VEGF or bevacizumab injections, inversely correlated with new onset visual impairments (R = -0.505, P = 0.027) in the hospital districts. The number of visual impairments did not differ between the hospital districts according to the PRN and TER protocols (1.23 ± 0.41 and 1.14 ± 0.67, respectively, per 1000 citizens aged ≥64 years, P = 0.713). These results emphasize that the use of aflibercept injections as a second-line treatment may decrease new onset visual impairments.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
472-476Informations de copyright
© 2020 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd.
Références
van Asten F, Michels CTJ, Hoyng CB et al. (2018): The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration - A cost-effectiveness analysis from a societal perspective. PLoS ONE 13: e0197670.
Aurell S, Sjovall K, Paul A, Moren A & Granstam E (2019): Better visual outcome at 1 year with antivascular endothelial growth factor treatment according to treat-and-extend compared with pro re nata in eyes with neovascular age-related macular degeneration. Acta Ophthalmol 97: 519-524.
Berg K, Hadzalic E, Gjertsen I et al. (2016): Ranibizumab or bevacizumab for neovascular age-related macular degeneration according to the lucentis compared to avastin study treat-and-extend protocol: two-year results. Ophthalmology 123: 51-59.
Berg K, Roald AB, Navaratnam J & Bragadottir R (2017): An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmol 95: 796-802.
Bhisitkul RB, Mendes TS, Rofagha S et al. (2015): Macular atrophy progression and 7-year vision outcomes in subjects from the ANCHOR, MARINA, and HORIZON studies: the SEVEN-UP study. Am J Ophthalmol 159: 915-924.e2.
Bloch SB, Larsen M & Munch IC (2012): Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 153: 209-213.
Borooah S, Jeganathan VS, Ambrecht AM et al. (2015): Long-term visual outcomes of intravitreal ranibizumab treatment for wet age-related macular degeneration and effect on blindness rates in south-east Scotland. Eye 29: 1156-1161.
Brody BL, Gamst AC, Williams RA et al. (2001): Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration. Ophthalmology 108: 1893-1900.
CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunewald JE, Fine SL & Jaffe GJ (2011): Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364: 1897-1908.
Chakravarthy U, Harding SP, Rogers CA et al. (2013): Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 382: 1258-1267.
Chin-Yee D, Eck T, Fowler S, Hardi A & Apte RS (2016): A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration. Br J Ophthalmol 100: 914-917.
Elshout M, Webers CAB, van der Reis MI & Schouten J (2018): A systematic review on the quality, validity and usefulness of current cost-effectiveness studies for treatments of neovascular age-related macular degeneration. Acta Ophthalmol 96: 770-778.
Ferris FL 3rd, Maguire MG, Glassman AR, Ying GS & Martin DF (2017): Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema. JAMA Ophthalmol 135: 145-149.
Gemenetzi M, Lotery AJ & Patel PJ (2017): Risk of geographic atrophy in age-related macular degeneration patients treated with intravitreal anti-VEGF agents. Eye 31: 1-9.
Gordois A, Cutler H, Pezzullo L et al. (2012): An estimation of the worldwide economic and health burden of visual impairment. Global Public Health 7: 465-481.
Heier JS, Brown DM, Chong V et al. (2012): Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119: 2537-2548.
Holash J, Davis S, Papadopoulos N et al. (2002): VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398.
Jorstad OK, Faber RT & Moe MC (2017): Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Acta Ophthalmol 95: 460-463.
Kataja M, Hujanen P, Huhtala H, Kaarniranta K, Tuulonen A & Uusitalo-Jarvinen H (2018): Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting. Br J Ophthalmol 102: 959-965.
Kvannli L & Krohn J (2017): Switching from pro re nata to treat-and-extend regimen improves visual acuity in patients with neovascular age-related macular degeneration. Acta Ophthalmol 95: 678-682.
Lee AY, Lee CS, Egan CA et al. (2017): UK AMD/DR EMR REPORT IX: comparative effectiveness of predominantly as needed (PRN) ranibizumab versus continuous aflibercept in UK clinical practice. Br J Ophthalmol 101: 1683-1688.
Maguire MG, Martin DF, Ying GS et al. (2016): Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology 123: 1751-1761.
Panchmatia HR, Clements KM, Hulbert E et al. (2016): Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden. Acta Ophthalmol 94: 441-448.
Quaggin SE (2012): Turning a blind eye to anti-VEGF toxicities. J Clin Invest 122: 3849-3851.
Rosenfeld PJ (2019): The LXXV Edward Jackson memorial lecture: lessons learned from avastin and OCT: the great, the good, the bad, and the ugly. Am J Ophthalmol 204: 26-45.
Rufai SR, Almuhtaseb H, Paul RM et al. (2017): A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab. Eye 31: 1337-1344.
Silva R, Berta A, Larsen M, Macfadden W, Feller C & Mones J (2018): Treat-and-extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the TREND study. Ophthalmology 125: 57-65.
Srinivasan S, Swaminathan G, Kulothungan V, Raman R & Sharma T (2017): Prevalence and the risk factors for visual impairment in age-related macular degeneration. Eye 31: 846-855.
Taipale C, Laine I & Tuuminen R (2019): Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration. Clin Ophthalmol 13: 17-23.
Taylor DJ & Hobby AE, Binns AM & Crabb DP (2016): How does age-related macular degeneration affect real-world visual ability and quality of life? A systematic review. BMJ Open 6: e011504.
Tuuminen R, Tuulonen A & Kaarniranta K (2017): The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration. Acta Ophthalmol 95: 649-650.
Tuuminen R, Uusitalo-Jarvinen H, Aaltonen V et al. (2017): The Finnish national guideline for diagnosis, treatment and follow-up of patients with wet age-related macular degeneration. Acta Ophthalmol 95: 1-9.
Tuuminen R, Sipila R, Komulainen J, Saarela V, Kaarniranta K & Tuulonen A (2019): The first ophthalmic Choosing Wisely recommendations in Finland for glaucoma and wet age-related macular degeneration. Acta Ophthalmol 97: e808-e810.
Vottonen P & Kankaanpaa E (2016): Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model. Acta Ophthalmol 94: 652-656.
Wykoff CC, Ou WC, Croft DE et al. (2018): Neovascular age-related macular degeneration management in the third year: final results from the TREX-AMD randomised trial. Br J Ophthalmol 102: 460-464.
Yanagi Y, Fukuda A, Barzey V & Adachi K (2017): Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan. J Med Econ 20: 204-212.
Zerbib J, Bourhis A, Cornut PL et al. (2017): Management of wet AMD in France in 2015. J Fr Ophtalmol 40: 723-730.
Zhang Y, Chioreso C, Schweizer ML & Abramoff MD (2017): Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies. Invest Ophthalmol Vis Sci 58: 5616-5627.